Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents
Crossref DOI link: https://doi.org/10.1007/s00280-015-2843-3
Published Online: 2015-08-11
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shukuya, Takehito
Ko, Ryo
Mori, Keita
Kato, Motoyasu
Yagishita, Shigehiro
Kanemaru, Ryota
Honma, Yuichiro
Shibayama, Rina
Koyama, Ryo
Shimada, Naoko
Takahashi, Kazuhisa
Text and Data Mining valid from 2015-08-11